Literature DB >> 24727570

Narcolepsy is a common phenotype in HSAN IE and ADCA-DN.

Keivan Kaveh Moghadam1, Fabio Pizza2, Chiara La Morgia2, Christian Franceschini3, Caterina Tonon4, Raffaele Lodi4, Piero Barboni5, Marco Seri6, Simona Ferrari6, Rocco Liguori2, Vincenzo Donadio7, Piero Parchi2, Ferdinando Cornelio8, Domenico Inzitari9, Andrea Mignarri10, Giuseppe Capocchi11, Maria Teresa Dotti10, Juliane Winkelmann12, Ling Lin13, Emmanuel Mignot13, Valerio Carelli2, Giuseppe Plazzi14.   

Abstract

We report on the extensive phenotypic characterization of five Italian patients from four unrelated families carrying dominant heterozygous DNMT1 mutations linked to two distinct autosomal dominant diseases: hereditary sensory and autonomic neuropathy with dementia and hearing loss type IE (HSAN IE) and autosomal dominant cerebellar ataxia, deafness and narcolepsy (ADCA-DN). Patients underwent genetic analysis of DNMT1 gene, neurophysiological tests investigating sleep, auditory functions and peripheral nervous system, ophthalmological studies including optical coherence tomography, lymphoscintigraphy, brain magnetic resonance and nuclear imaging, cerebrospinal fluid hypocretin-1, total tau, phosphorylated tau, amyloid-β1-42 and 14-3-3 proteins measurement, skin, muscular and sural nerve biopsies. Exome and direct sequencing studies disclosed two different point mutations affecting exon 21 of DNMT1 gene in patients with ADCA-DN, a novel heterozygous point mutation in exon 20 in two affected HSAN IE siblings, and a trinucleotide deletion in exon 20 in the latter patient with HSAN IE. Phenotypic characterization pinpoints that ADCA-DN and HSAN IE represent two discrete clinical entities belonging to the same disease spectrum, with variable degree of overlap. Remarkably, narcolepsy with or without cataplexy with low/intermediate or normal cerebrospinal fluid hypocretin-1 is present in both diseases. The human leukocyte antigen DQB1*06:02 was absent in all patients. Other common symptoms and features observed in our cases, involving the central and peripheral nervous system, include deafness, optic neuropathy-previously not reported in HSAN IE-large and small fibres polyneuropathy and lower limbs oedema. Overall, the two syndromes share more characteristics than previously recognized and narcolepsy is common to both. HSAN IE and ADCA-DN are two extreme phenotypic manifestations of a DNMT1 methylopathy.
© The Author (2014). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  ADCA-DN; DNMT1; HSAN IE; cataplexy; narcolepsy; neurodegeneration

Mesh:

Substances:

Year:  2014        PMID: 24727570     DOI: 10.1093/brain/awu069

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  13 in total

1.  Nocturnal Sleep Dynamics Identify Narcolepsy Type 1.

Authors:  Fabio Pizza; Stefano Vandi; Martina Iloti; Christian Franceschini; Rocco Liguori; Emmanuel Mignot; Giuseppe Plazzi
Journal:  Sleep       Date:  2015-08-01       Impact factor: 5.849

Review 2.  Germline Abnormalities in DNA Methylation and Histone Modification and Associated Cancer Risk.

Authors:  Jenna A Fernandez; Mrinal M Patnaik
Journal:  Curr Hematol Malig Rep       Date:  2022-06-02       Impact factor: 4.213

3.  Aberrant signature methylome by DNMT1 hot spot mutation in hereditary sensory and autonomic neuropathy 1E.

Authors:  Zhifu Sun; Yanhong Wu; Tamas Ordog; Saurabh Baheti; Jinfu Nie; Xiaohui Duan; Kaori Hojo; Jean-Pierre Kocher; Peter J Dyck; Christopher J Klein
Journal:  Epigenetics       Date:  2014-07-07       Impact factor: 4.528

4.  Cataplexy and ataxia: red flags for the diagnosis of DNA methyltransferase 1 mutation.

Authors:  Emanuela Postiglione; Elena Antelmi; Fabio Pizza; Stefano Vandi; Chiara La Morgia; Valerio Carelli; Stefania Nassetti; Marco Seri; Giuseppe Plazzi
Journal:  J Clin Sleep Med       Date:  2019-12-06       Impact factor: 4.062

5.  Defects of mutant DNMT1 are linked to a spectrum of neurological disorders.

Authors:  Jonathan Baets; Xiaohui Duan; Yanhong Wu; Gordon Smith; William W Seeley; Inès Mademan; Nicole M McGrath; Noah C Beadell; Julie Khoury; Maria-Victoria Botuyan; Georges Mer; Gregory A Worrell; Kaori Hojo; Jessica DeLeon; Matilde Laura; Yo-Tsen Liu; Jan Senderek; Joachim Weis; Peter Van den Bergh; Shana L Merrill; Mary M Reilly; Henry Houlden; Murray Grossman; Steven S Scherer; Peter De Jonghe; Peter J Dyck; Christopher J Klein
Journal:  Brain       Date:  2015-02-11       Impact factor: 13.501

6.  Narcolepsy type 1 features across the life span: age impact on clinical and polysomnographic phenotype.

Authors:  Althea Lividini; Fabio Pizza; Marco Filardi; Stefano Vandi; Francesca Ingravallo; Elena Antelmi; Oliviero Bruni; Filomena Irene Ilaria Cosentino; Raffaele Ferri; Biancamaria Guarnieri; Sara Marelli; Luigi Ferini-Strambi; Andrea Romigi; Enrica Bonanni; Michelangelo Maestri; Michele Terzaghi; Raffaele Manni; Giuseppe Plazzi
Journal:  J Clin Sleep Med       Date:  2021-07-01       Impact factor: 4.324

Review 7.  Medical management of hereditary optic neuropathies.

Authors:  Chiara La Morgia; Michele Carbonelli; Piero Barboni; Alfredo Arrigo Sadun; Valerio Carelli
Journal:  Front Neurol       Date:  2014-07-31       Impact factor: 4.003

8.  DNA methyltransferase 1 mutations and mitochondrial pathology: is mtDNA methylated?

Authors:  Alessandra Maresca; Mirko Zaffagnini; Leonardo Caporali; Valerio Carelli; Claudia Zanna
Journal:  Front Genet       Date:  2015-03-12       Impact factor: 4.599

9.  DNMT1 mutations found in HSANIE patients affect interaction with UHRF1 and neuronal differentiation.

Authors:  Martha Smets; Stephanie Link; Patricia Wolf; Katrin Schneider; Veronica Solis; Joel Ryan; Daniela Meilinger; Weihua Qin; Heinrich Leonhardt
Journal:  Hum Mol Genet       Date:  2017-04-15       Impact factor: 6.150

Review 10.  Optic neuropathies: the tip of the neurodegeneration iceberg.

Authors:  Valerio Carelli; Chiara La Morgia; Fred N Ross-Cisneros; Alfredo A Sadun
Journal:  Hum Mol Genet       Date:  2017-10-01       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.